Abstract
In this randomised, double-blind, placebo-controlled, 2-year multicentre study intrathecally administered natural human fibroblast interferon (IFN-B) was effective in reducing exacerbations of multiple sclerosis (MS) in patients with exacerbating/remitting disease. The mean reduction in exacerbation rate of 34 patients who received IFN-B (recipients) was significantly greater during the study than that of 35 patients who received placebo (p <0.04). The prestudy exacerbation rates were comparable in recipients and controls, but the rate at the end of the study was significantly lower in recipients than in controls (p <0.001). IFN-B was given by nine or ten lumbar punctures over the first 6 months of the study, and patient observations continued for 2 years. IFN-B was well tolerated in 95% of the recipients, and the side-effects experienced were clearly acceptable for the benefits achieved. Low doses of indomethacin reduced the toxicity of IFN-B and played an important role in successful double-blinding.
Footnotes
Presented in part at the annual meeting of the International Society for Interferon Research, Espoo, Finland, on Sept 12, 1986.
References
REFERENCES
- 1.Jacobs L., O'Malley J., Freeman A. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science. 1981;214:1026–1028. doi: 10.1126/science.6171035. [DOI] [PubMed] [Google Scholar]
- 2.Jacobs L., O'Malley J., Freeman A. Intrathecal interferon in multiple sclerosis. Arch Neurol. 1982;39:609–615. doi: 10.1001/archneur.1982.00510220007002. [DOI] [PubMed] [Google Scholar]
- 3.Stewart WE. - Springer-Verlag; New York: 1979. The interferon system. 249-56. [Google Scholar]
- 4.Cook Sd, Dowling Pc. Multiple sclerosis and viruses: an overview. Neurology. 1980;30:80–91. doi: 10.1212/wnl.30.7_part_2.80. [DOI] [PubMed] [Google Scholar]
- 5.Dunnick Jk, Galasso GT. Clinical tnals of exogenous interferon: summary of a meeting. J Infect Dis. 1979;139:109–123. doi: 10.1093/infdis/139.1.109. [DOI] [PubMed] [Google Scholar]
- 6.Leibowitz S. The immunology of multiple sclerosis. In: Hallpike Jf, Adams Cwm, Tourtellotte Ww., editors. Williams & Wilkins; Baltimore: 1983. pp. 379–412. (Multiple sclerosis.). [Google Scholar]
- 7.ter Meulen V., Stephenson Jr. The possible role of viral infection in multiple sclerosis and other related demyelinating diseases. In: Hallpike Jf, Adams Cwm, Tourtellotte Ww., editors. Baltimore Williams & Wilkins; 1983. pp. 241–274. (Multiple sclerosis.). [Google Scholar]
- 8.Salazar Am, Gibbs Cj, Gajdusek Dc. Clinical use of interferons: central nervous system disorders. In: Came P., Carter Wa, editors. Springer-Verlag; Berlin: 1983. pp. 472–497. (Handbook of experimental pharmacology.). [Google Scholar]
- 9.Emodi G., Just M., Hemandez R. Circulating IFN in man after administration of exogenous human leukocyte interferon. J Natl Cancer Inst. 1975;54:1045–1049. [PubMed] [Google Scholar]
- 10.DeClercq E., Edy Vg, DeVlieger H. Intrathecal administration of interferon in neonatal herpes. J Pediatr. 1975;86:736–739. doi: 10.1016/s0022-3476(75)80360-x. [DOI] [PubMed] [Google Scholar]
- 11.Habif Dv, Lipton R., Cantell K. Interferon crosses blod brain barrier in monkeys. Proc Soc Exp Biol Med. 1975;149:28–98. doi: 10.3181/00379727-149-38790. [DOI] [PubMed] [Google Scholar]
- 12.Hilfenhaus J., Weinmann E., Majer M. Administration of human interferon to rabies virus-infected monkeys after exposure. J Infect Dis. 1977;135:846. [PubMed] [Google Scholar]
- 13.Missett L., Mathe G., Horosewicz JS. Intrathecal interferon m meningeal leukemia. N Engl J Med. 1981;304:1544. doi: 10.1056/NEJM198106183042513. [DOI] [PubMed] [Google Scholar]
- 14.Prange H., Wismann Hn. Intrathecal use of interferon in encephalitis. N Engl J Med. 1981;305:1283–1284. doi: 10.1056/NEJM198111193052113. [DOI] [PubMed] [Google Scholar]
- 15.Smith Ra, Kingsbury D., Alksne J. Distribution of interferon in cerebrospinal fluid after systemic, intrathecal, and intraventricular administration. Ann Neurol. 1982;12:81. [Google Scholar]
- 16.Slatkin Ne, Jaeckle Ka, Lukes Sa. Treatment of leptomeningeal gliomatosis with human leukocyte interferon: results in two patients. Neurology. 1984;34:151. 1984. [Google Scholar]
- 17.Obbens Eamt, Feun Lg, Leavens Me. Interferon in the treatment of intracranial malignancies, a pilot study. Neurology. 1984;34:232. [Google Scholar]
- 18.Mora Js, Munsat Tl, Kao K-P. Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology. 1986;36:1137–1140. doi: 10.1212/wnl.36.8.1137. [DOI] [PubMed] [Google Scholar]
- 19.Jacobs L., O'Malley Ja, Freeman A. Intrathecal interferon as treatment of multiple sclerosis a planned multicenter study. Arch Neurol. 1983;40:683–686. doi: 10.1001/archneur.1983.04050100023008. [DOI] [PubMed] [Google Scholar]
- 20.McDonald WI. What is multiple sclerosis?: Clinical cntena for diagnosis. In: Davison An, Humphrey Jh, Liversedge Al, McDonald Wi, Porterfield Js., editors. vol 5. Elsevier; New York: 1975. p. 5. (Multiple sclerosis research). [Google Scholar]
- 21.Rose As, Kusma Jw, Kurtzke Jf. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo. final report. Neurology. 1970;20:1–159. doi: 10.1212/wnl.20.5_part_2.1. [DOI] [PubMed] [Google Scholar]
- 22.Brown Jr, Beebe Gw, Kurtzke Jf. The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology. 1979;29:3–23. doi: 10.1212/wnl.29.9_part_2.3. [DOI] [PubMed] [Google Scholar]
- 23.Poser Cm, Paty Dw, Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
- 24.Kurtzke Jf. Further notes on disability evaluation in multiple sclerosis, with scale modifications. Neurology. 1965;15:654–661. doi: 10.1212/wnl.15.7.654. [DOI] [PubMed] [Google Scholar]
- 25.Mora Js, Kao Kp, Munsat TL. Indomethacin reduces side effects of intrathecal interferon. N Engl J Med. 1984;310:126–127. doi: 10.1056/NEJM198401123100219. [DOI] [PubMed] [Google Scholar]
- 26.McAlpine D., Lumsden Ce, Acheson ED. Williams & Wilkins; Baltimore: 1972. Multiple sclerosis. a reappraisal. 185. [Google Scholar]
- 27.Antel Jp, Amason Bgw, Medof ME. Suppressor cell functions in multiple sclerosis correlation with clinical disease activity. Ann Neurol. 1979;5:338–342. doi: 10.1002/ana.410050406. [DOI] [PubMed] [Google Scholar]
- 28.Huddlestone Jr, Oldstone Mba. T Suppressor (Tg) lymphocytes fluctuate m parallel with changes in the clinical course of patients with multiple sclerosis. J Immunol. 1979;123:1615–1618. [PubMed] [Google Scholar]
- 29.Kadish As, Tansey Fa, Yu Gsm. Interferon as a mediator of human lymphocyte suppression. J Exp Med. 1980;151:637–650. doi: 10.1084/jem.151.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Onsrud M. Enhancement of suppressor cell generation in human mixed lymphocyte cultures by interferon. Int Arch Allergy Appl Immun. 1982;67:315–321. doi: 10.1159/000233040. [DOI] [PubMed] [Google Scholar]
- 31.Aune Tm, Pierce CW. Activation of a suppressor T-cell pathway by interferon. Proc Natl Acad Sci USA. 1982;79:3808–3812. doi: 10.1073/pnas.79.12.3808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Wong Ghw, Bartlett Pf, Clark-Lewis I. Inducible expression of H-2 and Ia antigens on brain cells. Nature. 1984;310:688. doi: 10.1038/310688a0. [DOI] [PubMed] [Google Scholar]
- 33.Bukowski Jf, Welsh RM. IFN enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells. J Exp Med. 1985;161:257–262. doi: 10.1084/jem.161.1.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Suzumura A., Lavi E., Weiss Sr. Coronavirus infection induces H-2 antigen expression on oligodendrocytes and astrocytes. Science. 1986;232:991–992. doi: 10.1126/science.3010460. [DOI] [PubMed] [Google Scholar]
- 35.Rose J., Salazar Am. Characterization of the cerebrospinal fluid pleocytosis induced by intrathecal administration of beta-interferon. Ann Neurol. 1986;20:166. [Google Scholar]
- 36.Panitch Hs, Hirsh Rl, Schindler J. Immunological correlates of disease activity m multiple sclerosis patients treated with gamma interferon. Ann Neurol. 1986;20:124. [Google Scholar]
- 37.Lisak RP. Interferon and multiple sclerosis. Ann Neurol. 1986;20:273. doi: 10.1002/ana.410200217. [DOI] [PubMed] [Google Scholar]
- 38.Billiau A. Interferon therapy pharmacokinetic and pharmacological aspects. Arch Virol. 1981;67:121–123. doi: 10.1007/BF01318595. [DOI] [PubMed] [Google Scholar]
- 39.Smith Ra, Landel C., Cornelius Ce. Mapping the action of interferon on the primate brain. J Interferon Res. 1986;5(suppl 1):140. [Google Scholar]
- 40.Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun. 1982;11:1–7. doi: 10.3109/08820138209050718. [DOI] [PubMed] [Google Scholar]
- 41.Abreu Sl, Tondreau J., Levine S., Sowinski R. Inhibition of passive localized allergic encephalomyelitis by IFN. Int Arch Allergy Appl Immunol. 1983;72:30–33. doi: 10.1159/000234836. [DOI] [PubMed] [Google Scholar]
- 42.Hertz F., Deghenghi R. Effect of rat and human B-IFN on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions. 1985;16:397. doi: 10.1007/BF01982879. [DOI] [PubMed] [Google Scholar]
- 43.Jacobs L., O'Malley Ja, Freeman A. Intrathecal interferon in the treatment of multiple sclerosis patient follow-up. Arch Neurol. 1985;42:841–847. doi: 10.1001/archneur.1985.04060080019009. [DOI] [PubMed] [Google Scholar]
- 44.L. Jacobs, Am Salazar, R. Herndon, et al., Intrathecal interferon in the treatment of multiple sclerosis In: Ra Smith (Eds), Interferons in the treatment of neurologic disorders., Marcel Dekker, New York ((in press)).
- 45.L. Jacobs, Am Salazar, JA. O'Malley, The use of interferons in the treatment of certain diseases of the central nervous system In: S. Baron (Eds), The interferon system, a current review Galveston, University of Texas Press (in press)).